SCREENING FOR A 10-GENE PANEL IN A GROUP OF 90 PHAEOCHROMOCYTOMAS

Emilia Sbardella1,4, Radu Mihai2, Treena Cranston3, Ashley Grossman1
Departments of 1Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, 2Endocrine Surgery and 3Clinical Genetics
Oxford University Hospitals NHS Foundations Trust, Oxford, UK
4 Department of Experimental Medicine, Sapienza University of Rome, Italy

Background
Several new gene mutations have been reported in recent years to be associated with a risk of familial phaeochromocytomas. However, it remains unclear as to whether there is a genotype-phenotype correlation that could be used in clinical decisions in a similar fashion as is currently done for RET and VHL mutations.

Methods
Clinical data of consecutive unselected as operated for phaeochromocytomas (PHAEOs) over a decade in a tertiary referral centre were reviewed. Genetic screening was performed using a 10-gene panel comprising RET, VHL, SDHB, SDHD, SDHA, SDHC, SDHAF2, MAX, TMEM127 (TMEM127 and SDHB if >45 years, NF1 when indicated).

Results
A total of 157 patients (68 males: 43%, 89 females: 57% 6-86 years, median 50.3±17.4 years) underwent laparoscopic (85%), open (10.5%), or laparoscopic converted to open (4.5%) adenectomy for unilateral (92%) or bilateral (8%) adrenal phaeochromocytomas: 90 patients underwent genetic screening, in particular 60/90 (67%) patients presented with apparently sporadic tumours and 30/90 (33%) patients had genetic mutations. These were more frequently bilateral (p=0.02). In particular, mutations were seen in 11/90 patients for VHL (12%), 9/90 NF1 (10%), 6/90 RET (7%), 2/90 patients SDH2 (2%) and 2 patients MAX (2%). During a median follow-up of 50.4 months (1-240 months), 12 patients (8%) presented with recurrence in the contralateral adrenal (n=8: 5%) or with metastatic disease from malignant phaeochromocytomas (n=11: 7%). Younger patients showed a significant higher percentage of mutations compared to older patients (24/54: 44% vs 8/36: 17%). 20/74 (27%) mutations were identified in patients who presented with unilateral phaeochromocytoma and showed no disease recurrence within 5 years vs 10/16 (62%) in the recurrent-bilateral-metastatic group. 6/7 (86%) patients with bilateral disease had germline mutations (2 VHL, 2 RET, 1 NF1, 1 MAX).

Conclusions
The advent of rapid genetic screening for 10-gene panel makes it feasible to screen large cohorts of patients, and allows for the prediction of bilateral and malignant disease and screening of family members.

References